Document is current
Any future updates will be listed below
-
Authors
Bansal, Sandeep
Anderson, Martin
Anzueto, Antonio
Brown, Nicola
Compton, Chris
Corbridge, Thomas C.
Erb, David
Harvey, Catherine
Kaisermann, Morrys C.
Kaye, Mitchell
Lipson, David A. https://orcid.org/0000-0001-6732-4593
Martin, Neil
Zhu, Chang-Qing
Papi, Alberto https://orcid.org/0000-0002-6924-4500
-
Funding
Funding for this research was provided by:
GlaxoSmithKline
- License Information
-
More Information
Article History
Received: 10 September 2020
Accepted: 19 April 2021
First Online: 25 May 2021
Competing interests
: S.B. has received speaker fees from GSK, Boehringer Ingelheim, Auris Health, Veran, Veracyte, Biodesix, Pinnacle Biologics, and Circulogene. He has also previously participated in speaker’s bureau for Sunovion Pharmaceuticals and holds stocks/shares in Veracyte. M.A. has received speaker fees from AstraZeneca, Boehringer Ingelheim, GSK, MEDA, Orion Pharma, and TEVA. A.A. has received consultancy fees from Boehringer Ingelheim, Novartis, AstraZeneca, and Theravance Mylan. N.B., C.C., T.C.C., C.H., M.C.K., D.A.L., N.M., and C.-Q.Z. are employees of GSK and own stocks/shares. D.E. has received compensation for being a trial investigator for Vitalink Research. M.K. has nothing to disclose. A.P. has received consultancy fees and board membership from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Mundipharma, and TEVA, and consultancy fees and payment for lectures from Sanofi. He has also received reimbursement of travel expenses from Avillion, reimbursement of travel expenses and payment for lectures from AstraZeneca, Boehringer Ingelheim, Chiesi, ELPEN Pharmaceutical, GSK, Menarini, MSD, Mundipharma, Novartis, TEVA, and Zambon, and research grants from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Pfizer, Sanofi, and TEVA.
